Welcome to the Horizon 2020 atherosclerosis research program website
The link between hematopoiesis and atherosclerosis
REPROGRAM Principal Investigators working at Amsterdam University Medical Center and Ludwig Maximilians University, Munich published their expert comments on the link between hematopoiesis and atherosclerosis, based on the following article “AIBP-mediated cholesterol efflux instructs hematopoietic stem and progenitor cell fate” in Science. 2019. There is mounting evidence that atherosclerosis is driven not just by dyslipidemia
Oligomeric S100A4 Is Associated With Monocyte Innate Immune Memory and Bypass of Tolerance to Subsequent Stimulation With Lipopolysaccharides.
Most DAMPs in inflammatory diseases are TLR2- and TLR4-ligands and according to the current concept, repeated stimuli would result in tolerance. Aims of the study were to verify this assumption, to investigate whether epigenetic effectors are involved and to explore the situation in rheumatoid arthritis (RA).
New scientific article in Cell metabolism 2019.
Patients with hypercholesterolemia have an increased risk for atherosclerotic cardiovascular disease, and despite lipid lowering with statins, an important residual risk remains. We hypothesize that this is due to persistent pro-inflammatory reprogramming of circulating monocytes. Monocyte derived macrophages are key components of atherosclerotic plaques. These cells can build a long-term pro-inflammatory phenotype after brief exposure
Satellite‐congress EAS 2019
Over 50 participants attended the inspiring satellite-congress EAS 2019, co-organized by REPROGRAM, focused on the “Interplay of metabolism, inflammation and vascular biology”. On behalf of REPROGRAM Prof. Niels Riksen (Radboud UMC), Prof. Erik Stroes (Academic Medical Center) and Prof. Matthias Nahrendorf (Harvard Medical School) presented their work and emerging results. This symposium was open to
Joint session (open-end conference) of the REPROGRAM project at the EAS SATELLITE on IMMUNOMETABOLISM (26 May 2019)
Open-end congres REPROGRAM at EAS
On May 26 until May 29 2019 the open-end congres of REPROGRAM will be held at the 87th European Atherosclerosis Society in Maastricht. You can sign in with the following link: https://eas2019.com/the-congress/satellite-symposia/immunometabolism/ Untitled
Grant application MEMORY funded by European Research Area Network on Cardiovascular Diseases (ERA-CVD)
Prof. Niels RIksen (RadboudUmc, Nijmegen) teamed up with dr. Andreas Schlitzer (University of Bonn, Germany) and dr. Hafid Ait-Oufella (St-Antoine Hospital and Inserm , France). They prepared a successful transnational ERA-CVD research application entitled MEMORY. Due to the worldwide adoption of Western lifestyle, the prevalence of obesity increases exponentially. Obesity is an important risk factor for
Governing Council meeting 2019
On January 21 2019, the Governing Council meeting was held at Schiphol Amsterdam airport for the REPROGRAM project. After a warm welcome by Prof. Dr. Erik Stroes (Project Coordinator) the meeting started immediately with presentations of Prof. dr. Niels Riksen (RadboudUMC), Prof. dr. Erik Stroes (AMC), Prof dr.Borge Nordestgaard (Copenhagen University Hospital) and Prof. dr.
Review article in Atherosclerosis: “Potential epigenetic therapeutics for atherosclerosis treatment”
The AMC groups of Prof. Stroes and Prof. de Winther published recently a review article on epigenetic therapeutics for atherosclerosis in the Atherosclerosis journal. Common epigenetic modifications such as DNA methylation and histone post-translational modifications are in the spotlight of epigenetic therapeutics and are show promise for the treatment of many diseases including cancer, diabetes,
Analyses in the primary prevention setting substantiate that LDL-C and Lp(a) are independently associated with CVD risk.
Lipoprotein(a) (Lp(a)) elevation is a causal risk factor for cardiovascular disease. It has however been suggested that elevated Lp(a) causes cardiovascular disease mainly in individuals with high low-density lipoprotein cholesterol (LDL-C) levels. Therefore it was hypothesized that the risk associated with high Lp(a) levels would largely be attenuated at low LDL-C levels. Results from the Copenhagen City Heart
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.
